Prognostic value of sarcopenia on survival outcomes in patients undergoing surgical treatment for gastric cancer
- 27 January 2026
- journal article
- Published by Turkish Journal of Clinics and Laboratory in TURKISH JOURNAL of CLINICS and LABORATORY
- No. 1
Abstract
Aim: This study aims to assess the predictive impact of sarcopenia on survival in individuals with surgically treated gastric cancer.Material and Methods: This retrospective analysis examined individuals who underwent surgery for gastric cancer, categorizing them into sarcopenia and non-sarcopenia groups based on skeletal muscle index from abdominal CT images. The study assessed clinicopathological variables, survival, and prognosis differences between the groups.Results: The median age of the 84 patients was 59 years (range, 24–80); 64.3% were male. For all patients, 67.9% (n = 57) had sarcopenia and 32.1% (n = 27) did not. According to the ROC analysis, the predictive performance of sarcopenia for mortality was statistically significant (AUC = 0.694; p = 0.012). The best cut-off value of 24.97 yielded 75.8% sensitivity and 61.1% specificity. The median follow-up was 48.6 months, and 18 patients (21.4%) died. Sarcopenia patients had a median survival of 32 months (95% CI: 27.4–36.6), while non-sarcopenic patients had 56 months (95% CI: 43.2–68.8). Sarcopenia was an independent survival predictive factor in multivariate Cox regression (HR = 2.46; 95% CI: 1.24–4.87; p = 0.010).Conclusion: The identification of sarcopenia through CT imaging at the time of diagnosis in patients with gastric cancer is associated with overall survival rates and serves as a prognostic marker for poor prognosis.Keywords
This publication has 21 references indexed in Scilit:
- SarcopeniaNature Reviews Disease Primers, 2024
- Comparative study of cancer profiles between 2020 and 2022 using global cancer statistics (GLOBOCAN)Journal of the National Cancer Center, 2024
- Body composition and cancer survival: a narrative reviewBritish Journal of Cancer, 2023
- Sarcopenia prevalence in patients with cancer and association with adverse prognosis: A nationwide survey on common cancersNutrition, 2023
- Muscle mass, assessed at diagnosis by L3-CT scan as a prognostic marker of clinical outcomes in patients with gastric cancer: A systematic review and meta-analysisClinical Nutrition, 2020
- Management of Gastrointestinal Symptoms (Nausea, Anorexia and Cachexia, Constipation) in Advanced IllnessMedical Clinics of North America, 2020
- Gender Differences in Gastric Cancer Survival: 99,922 Cases Based on the SEER DatabaseJournal of Gastrointestinal Surgery, 2020
- Sarcopenia and physical independence in older adults: the independent and synergic role of muscle mass and muscle functionJournal of Cachexia, Sarcopenia and Muscle, 2016
- Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic reviewEuropean Journal of Cancer, 2016
- Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung CancerJournal of Thoracic Oncology, 2015